Thu, Jul 10, 2014, 3:42 AM EDT - U.S. Markets open in 5 hrs 48 mins

Recent

% | $
Quotes you view appear here for quick access.

Cellceutix Corporation Message Board

charleysimp 14 posts  |  Last Activity: Jun 29, 2014 8:36 PM Member since: Oct 20, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • charleysimp by charleysimp Jun 29, 2014 8:36 PM Flag

    so fixated on the single dose that if only the 3 dose works the share price will drop?

  • charleysimp charleysimp Jun 18, 2014 8:50 PM Flag

    looks like there are a few university's running tests on our drugs

  • charleysimp charleysimp Jun 18, 2014 8:49 PM Flag

    cont.

    Three compounds were tested as topical agents in two different mouse models of oral candidiasis and were found to be highly active. Following single dose administrations, total Candida burden in tongues of infected animals were reduced up to three logs. These studies highlight the potential of HDP mimetics as a new tool in the antifungal arsenal for the treatment of oral candidiasis.
    FOOTNOTES

    ↵#Correspondence and present address: Dr. Gill Diamond, Department of Oral Biology, University of Florida, Box 100424, Gainesville, FL 32610,

  • charleysimp charleysimp Jun 18, 2014 8:28 PM Flag

    this looks like another one of ours from April 2014

    Activity of Potent and Selective Host Defense Peptide Mimetics in Mouse Models of Oral Candidiasis
    Lisa K. Ryan1, Katie B. Freeman2, Jorge A. Masso-Silva3, Klaudia Falkovsky3, Ashwag Aloyouny3, Kenneth Markowitz3, Amy G. Hise4,5,6, Richard W. Scott2 and Gill Diamond3#

    + Author Affiliations
    1Public Health Research Institute and Department of Medicine, New Jersey Medical School, Rutgers, the State University of New Jersey, Newark, NJ 07103
    2Fox Chase Chemical Diversity Center, Doylestown, PA
    3Department of Oral Biology, Rutgers School of Dental Medicine, Newark, NJ 07101
    4Department of Pathology, Case Western Reserve University, Cleveland, OH, USA
    5Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA
    6Medical Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, OH, USA.

    ABSTRACT

    There is a strong need for new broadly active antifungal agents for the treatment of oral candidiasis that are not only active against many species of Candida, including drug-resistant strains, but also evade microbial countermeasures which may lead to resistance. Host defense peptides (HDPs) can provide a foundation for the development of such agents. Toward this end, we have developed fully synthetic, small-molecule, non-peptide mimetics of the HDPs that improve safety and other pharmaceutical properties. Here we describe the identification of several HDP mimetics that are broadly active against C. albicans and other species of Candida, rapidly fungicidal, active against yeast and hyphal cultures and that exhibit low cytotoxicity for mammalian cells. Importantly, specificity for Candida over commensal bacteria was also evident thereby minimizing potential damage to the endogenous microbiome which otherwise could favor fungal overgrowth.

  • charleysimp charleysimp Jun 18, 2014 8:16 PM Flag

    Nice find cinreho

    This is an earlier article by William DeGrado. It looks like he may have worked at The University of Pennsylvania.

    Antibacterial mechanism of action of arylamide foldamers.
    Antimicrob. Agents Chemother.
    Antimicrob Agents Chemother 2011 Nov 15;55(11):5043-53. Epub 2011 Aug 15.
    Bruk Mensa, Yong Ho Kim, Sungwook Choi, Richard Scott, Gregory A Caputo, William F DeGrado

    Small arylamide foldamers designed to mimic the amphiphilic nature of antimicrobial peptides (AMPs) have shown potent bactericidal activity against both Gram-negative and Gram-positive strains without many of the drawbacks of natural AMPs. These foldamers were shown to cause large changes in the permeability of the outer membrane of Escherichia coli. They cause more limited permeabilization of the inner membrane which reaches critical levels corresponding with the time required to bring about bacterial cell death. Transcriptional profiling of E. coli treated with sublethal concentrations of the arylamides showed induction of genes related to membrane and oxidative stresses, with some overlap with the effects observed for polymyxin B. Protein secretion into the periplasm and the outer membrane is also compromised, possibly contributing to the lethality of the arylamide compounds. The induction of membrane stress response regulons such as rcs coupled with morphological changes at the membrane observed by electron microscopy suggests that the activity of the arylamides at the membrane represents a significant contribution to their mechanism of action.
    Affiliation
    Department of Biochemistry and Biophysics, University of Pennsylvania, 1010 Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, Pennsylvania 19104-4860, USA.

  • charleysimp by charleysimp Jun 16, 2014 8:19 PM Flag

    Carbocyclic nucleosides and their pharmaceutical use and compositions

    Publication number WO2013103601 A1
    Publication type Application
    Application number PCT/US2012/072103
    Publication date Jul 11, 2013
    Filing date Dec 28, 2012
    Priority date Jan 3, 2012
    Inventors Krishna Menon
    Applicant Cellceutix Corporation

  • charleysimp charleysimp Jun 9, 2014 6:04 PM Flag

    Here's one of Leos replies to an email from an ihub poster on 01/20/14

    Ihub poster
    3)" Will you attempt to partner Brilicidin before a 2b readout?"

    Leo
    " Not for ABSSSI. For other indications where there is significant upfront costs we would look to do such as soon as more data from the phase 2 trial is available."

  • charleysimp charleysimp Jun 2, 2014 10:31 PM Flag

    Charley thinks one day the trial will be over, whatever cohort it reaches, and all the facts will be known.

  • charleysimp by charleysimp May 27, 2014 6:53 PM Flag

    From today's days PR "the Company has signed material transfer agreements for compounds in its defensin mimetics portfolio with major university laboratories located in New York and New Jersey. These laboratories do significant government work and have expertise in anti-infective, anti-fungal and bio-defense applications.

    This is my guess of which drugs and which university's after doing a little research

    The compounds they may be talking about in today's PR may be PMX1502 and PMX1408 which were mentioned in a PR back in November which they seemed excited about advancing.

    and the universities they may be talking about could be The State University of New York at Buffalo and Rutgers The State University of New Jersey.

    They both have expertise in anti-infective, anti-fungal applications according to Google.

  • charleysimp charleysimp May 26, 2014 2:39 PM Flag

    This was in a CTIX press release last year that mentions REVLIMID®
    (lenalidomide) but it doesn't particularly say there is a combo trial with
    Kevetrin and Revlimid.

    "MD Anderson intends to utilize in vivo and in vitro methods to research specific pathways, gene expression, mechanism of action and apoptotic activity of Kevetrin in a range of concentrations and time points in both mutant and wild-type p53 Myeloma and Lymphoma cell lines. Research is also planned to evaluate Kevetrin against models of Multiple Myeloma cell lines that are resistant to bortezomib, lenalidomide and other FDA-approved chemotherapies. Additional studies will be conducted evaluating the anti-tumor activity of Kevetrin when used as a combination therapy with several FDA-approved drugs. MD Anderson will provide funding for these studies of Kevetrin defined by the MTA."

  • Reply to

    Diabetic Foot Wound and Ulcer

    by z_for_three May 19, 2014 7:35 AM
    charleysimp charleysimp May 21, 2014 5:23 PM Flag

    Agreed. It Looks like the Brilacidin mouse has a comb over.

  • charleysimp by charleysimp May 12, 2014 5:48 PM Flag

    Specifically this

    "As we are advancing in this ABSSSI trial, our acquisition of Brilacidin is confirming our initial assessments and expectations of the compound," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We are well on our way towards fruition of our goals set for this drug."

    Being its a double blind trial and there is no way Leo knows which patients are in which ARM to me means most if not all of them are showing efficacy. Also I wouldn't be surprised if we see SAEs before the end of the trial being one of the ARMs is Daptomycin which had SAEs in the 2A.

    Any PR that doesn't contain bad news is good news and brings us one step closer to our end goal, which is a nice return of our investment.

  • Reply to

    CTIX

    by gizmo_puppy95 Apr 25, 2014 1:05 PM
    charleysimp charleysimp Apr 26, 2014 9:56 AM Flag

    Hey Fraz do you think an antibiotic ointment is in the cards? maybe Brilasporin perhaps.

  • charleysimp charleysimp Apr 12, 2014 8:32 AM Flag

    It is...and Prurisol and Kevetrin.

CTIX
1.668-0.012(-0.71%)Jul 9 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.